DYNAVAX TECHNOLOGIES

DVAX
Delayed Quote. Delayed  - 01/19 04:00:00 pm
5.1USD -0.58%

Turn to zoom
Prev.5.1300
Open5.1500
High5.3200
Low5.0700
Volume2 583 206
Latest news
7d ago
01/07
01/07
12/29
Chart DYNAVAX TECHNOLOGIES CORPORATION
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBearishNeutral
Resistance5,606,0111,4
Spread/Res.-8,9%-15%-55%
Spread/Supp.15%37%112%
Support4,453,732,41
Financials
Sales 2020 40,1 M - -
Net income 2020 -87,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -5,93x
Yield 2020 -
Capitalization 562 M 562 M -
Capi. / Sales 2020 14,0x
Capi. / Sales 2021 4,51x
Nbr of Employees 231
Free-Float 99,2%
Company
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a...

>> Read more
Sector :
Bio Therapeutic Drugs
Calendar :
2021-03-11 Earnings Release
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Mean consensus BUY
Number of Analysts 4
Average target price 16,00 $
Last Close Price 5,10 $
Spread / Highest target 292%
Spread / Average Target 214%
Spread / Lowest Target 175%